淋巴结阳性乳腺癌：最佳化疗方案有哪些？
Node-positive Breast Cancer: Which Are the Best Chemotherapy Regimens?
作者信息
Janni Wolfgang, Rack Brigitte, Harbeck Nadja, Bauerfeind Ingo, Sommer Harald, Friese Klaus
机构信息
Frauenkliniken Innenstadt und Großhadern, Klinikum der Ludwig-Maximilians-Universität, München.
出版信息
Breast Care (Basel). 2008;3(4):244-250. doi: 10.1159/000149099. Epub 2008 Aug 22.
Abstract
Breast cancer-associated mortality has been significantly reduced since the 1990s, mainly because of early diagnosis and systemic therapeutic interventions. All three therapy components - cytostatic therapy, endocrine therapy and targeted antibody therapy - are at present necessary tools for the curative treatment of primary breast cancer. This article reviews the evidence base for the use of various chemotherapy schedules in patients with primary, node-positive breast cancer, including schedules in combination with targeted HER2/neu therapy.
摘要
自20世纪90年代以来，乳腺癌相关死亡率已显著降低，这主要归功于早期诊断和系统性治疗干预。目前，细胞毒性疗法、内分泌疗法和靶向抗体疗法这三种治疗手段都是原发性乳腺癌根治性治疗的必要工具。本文回顾了原发性、淋巴结阳性乳腺癌患者使用各种化疗方案的循证依据，包括与HER2/neu靶向治疗联合使用的方案。
相似文献
1
Node-positive Breast Cancer: Which Are the Best Chemotherapy Regimens?淋巴结阳性乳腺癌：最佳化疗方案有哪些？
Breast Care (Basel). 2008;3(4):244-250. doi: 10.1159/000149099. Epub 2008 Aug 22.
2
The curability of breast cancer and the treatment of advanced disease.乳腺癌的可治愈性及晚期疾病的治疗
Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S149-61. doi: 10.1007/s00259-004-1538-5. Epub 2004 Apr 24.
3
Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.早期女性乳腺癌的辅助化疗：对2014年安大略癌症护理系统治疗指南证据的系统评价
Curr Oncol. 2015 Mar;22(Suppl 1):S82-94. doi: 10.3747/co.22.2321.
4
HER2-Positive Early Breast Cancer: Time for Ultimate De-Escalation?人表皮生长因子受体2阳性早期乳腺癌：是时候进行最终的降阶梯治疗了吗？
Cancers (Basel). 2024 Mar 11;16(6):1121. doi: 10.3390/cancers16061121.
5
Treatment of breast cancer.乳腺癌治疗。
Am Fam Physician. 2010 Jun 1;81(11):1339-46.
6
Adjuvant Systemic Therapy of Breast Cancer.乳腺癌的辅助全身治疗
Breast Care (Basel). 2011;6(3):179-183. doi: 10.1159/000329336. Epub 2011 Jun 3.
7
Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.临床淋巴结阳性、HER2 阳性乳腺癌中，新辅助单药或双药人表皮生长因子受体 2（HER2）阻断的腋窝反应。
Int J Cancer. 2021 Oct 15;149(8):1585-1592. doi: 10.1002/ijc.33726. Epub 2021 Jul 8.
8
The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease.激素受体阳性、人表皮生长因子受体 2（HER2）阴性乳腺癌治疗复杂性的演变：老年乳腺癌患者的特殊考虑因素-第 1 部分：早期疾病。
Drugs Aging. 2020 May;37(5):331-348. doi: 10.1007/s40266-020-00748-z.
9
Taxanes for adjuvant treatment of early breast cancer.紫杉烷类用于早期乳腺癌的辅助治疗。
Cochrane Database Syst Rev. 2019 Sep 2;9(9):CD004421. doi: 10.1002/14651858.CD004421.pub3.
10
Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence.阿贝西利：复发风险高的早期乳腺癌综述
Target Oncol. 2023 Mar;18(2):287-294. doi: 10.1007/s11523-023-00952-y. Epub 2023 Feb 24.
本文引用的文献
1
On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases.论乳癌不可手术病例的治疗：一种新治疗方法的建议及实例说明
Trans Med Chir Soc Edinb. 1896;15:153-179.
2
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.人表皮生长因子受体2（HER2）状态与早期乳腺癌辅助性蒽环类药物的疗效：随机试验的汇总分析
J Natl Cancer Inst. 2008 Jan 2;100(1):14-20. doi: 10.1093/jnci/djm252. Epub 2007 Dec 25.
3
I. The Results of Radical Operations for the Cure of Carcinoma of the Breast.一、乳腺癌根治手术的治疗结果
Ann Surg. 1907 Jul;46(1):1-19. doi: 10.1097/00000658-190707000-00001.
4
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.进展与前景：2007年早期乳腺癌主要治疗国际专家共识要点
Ann Oncol. 2007 Jul;18(7):1133-44. doi: 10.1093/annonc/mdm271.
5
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.一项III期试验，比较多柔比星联合环磷酰胺与多西他赛联合环磷酰胺作为可手术乳腺癌辅助治疗的效果。
J Clin Oncol. 2006 Dec 1;24(34):5381-7. doi: 10.1200/JCO.2006.06.5391.
6
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.早期乳腺癌放疗及手术范围差异对局部复发和15年生存率的影响：随机试验综述
Lancet. 2005 Dec 17;366(9503):2087-106. doi: 10.1016/S0140-6736(05)67887-7.
7
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.曲妥珠单抗联合辅助化疗用于可手术的HER2阳性乳腺癌
N Engl J Med. 2005 Oct 20;353(16):1673-84. doi: 10.1056/NEJMoa052122.
8
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.HER2阳性乳腺癌辅助化疗后使用曲妥珠单抗。
N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/NEJMoa052306.
9
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.早期乳腺癌化疗和激素治疗对复发及15年生存率的影响：随机试验综述
Lancet. 2005;365(9472):1687-717. doi: 10.1016/S0140-6736(05)66544-0.
10
A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer.乳腺癌前哨淋巴结活检与常规腋窝淋巴结清扫的随机对照研究
N Engl J Med. 2003 Aug 7;349(6):546-53. doi: 10.1056/NEJMoa012782.
Zotero 插件